A Study for HSK39775 in Participants With Solid Tumors
Trial Parameters
Brief Summary
This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older at screening 2. Histological or cytological confirmation of advanced malignancy, have failed or intolerant to the standard-of-care treatment or no standard therapy is recognized or standard therapy is unavailable 3. Eastern Cooperative Oncology Group performance status 0 or 1 4. Patients must have evaluable disease as defined 5. Life expectancy of ≥ 12 weeks 6. Adequate organ and bone marrow function per protocol 7. Female patients who are women of childbearing potential with confirmed of a negative pregnancy test within 7 days prior to the first dose and agreement to the use of effective contraceptive method at the same time during study treatment period and for up to 6 months after the last dose of study treatment. Male patients must be willing to use effective contraception during the study treatment period and for up to 6 months after the last dose of study treatment 8. Written informed consent must be obtained Exclusion Criteria: 1. Kno